Compare Johnson & Johnson (JNJ) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs MasTec Inc — how do they compare? Johnson & Johnson trades at $260.9 (market cap $618.09B), while MasTec Inc trades at $214.47 (market cap $17.40B). The key difference: Johnson & Johnson is far larger — about 35.5× MasTec Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and MasTec Inc for 23 Days on average.
| JNJ | MTZ | |
|---|---|---|
Market Cap | $618.09B | $17.40B |
Volume | 6,050,983 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $278.43 | $437.51 |
52-Week Low | $186.00 | $190.08 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $646.37B | $20.32B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
MasTec (MTZ) trades at $216.11, down 3.25% on the day, with technical indicators showing a bearish trend as the stock trades below key moving averages. The company maintains strong fundamentals with revenue growth from $14.3B in 2025 to $16.1B projected for 2026, and net income improving to $494M. Recent news highlights MTZ's positioning in infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4B backlog.
The outlook remains positive given analyst consensus of 32 Buy ratings and a $408.58 price target, representing 89% upside potential. Key risks include premium valuation metrics (P/E 34.5), weak cash flow trends, and communications segment softness. The stock's current discount to analyst targets presents a compelling opportunity if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
